Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.24-0.90 (-8.88%)
At close: 1:00PM EST
9.49 +0.25 (+2.71%)
After hours: 03:45PM EST
Advertisement
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals reached an all time low at 9.35
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals reached an all time low at 9.80
  • L
    Lisi
    Why RYTM keeps dropping after good news? What kind of stock is it?
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals reached an all time low at 10.58
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals is down 8.78% to 9.25
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals is down 8.22% to 10.50
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals is up 7.85% to 13.05
  • Y
    Yahoo Finance Insights
    Rhythm Pharmaceuticals is up 7.13% to 13.82
  • C
    Captainkgood
    I posted this about a week ago.

    Here’s what I found about a PRIME candidate for the EMA.

    “Accelerated assessment reduces the evaluation of a centralized marketing authorization application to 150 days. The standard timeframe could be as much as 210 days depending on clock‐stops initiated by requests
    for further information.”

    That would make the review only 5 months if all went to plan. According to a comany press release on Jul 1,2020, RYTM applied with the European agency in June. That would mean 150 days was in November.

    It should be any day now for European approval.

    And the additional study data at the end of the year could solidify interest from large pharma, but at least show the promise for expanded use of setmelanotide into other syndromes, etc.
  • C
    Captainkgood
    Anyone here loading up for a run, should RYTM get FDA approval. I’m feeling pretty confident about the chances based on the latest data and the need. Does anyone else think that this drug could be expanded into other uses? Seems that it could be a potentially huge market for weight loss for other health needs. Diabetes, etc.
  • R
    RONALD
    I do my research before buying stocks. There is an 4 years ago company presentation which described the objectives of the testing to get an approval. They are hiring more employees in the last month and approval is coming soon. The stock has started to rise rapidly last month. I have it up $.72 in after hours trading. Good sign.
    Bullish
  • P
    Paul
    Regarding target market.. It's common for drug company to apply for rare disease to get FDA fast tract or orphan designation, then target entire population after approval.
  • Z
    Zanadeux
    This stock was featured by Stansberry Venture Technology and brought to my attention by Stock Gumshoe....wondering if that is what made it pop today?
  • H
    Harry
    Some of you may remember OREX which was a company pursuing obesity. It came with a bang around 2015-16 and then died without a splash. It is now defunct or bankrupt. Everyone was gung-ho over its prospects given the wide prevalence of and growing incidence of obesity in US and elsewhere.

    Could someone chime in on why this time should be different.

    There is something about the obesity environment that is hard to get an understanding of. Why such a failure despite such a seemingly huge market.

    Thanks for watching and hope to have some educated inputs. TIA
  • n
    norman
    25M shares just dropped this 3/4 pt. Only 5% in retail non-inst/insider hands=approx 2.2 mill shares; last 3 das. transaction vols.=2/+ mill. shrs., most at 30/+; theoretically, given FDA news/future, RYTM should go up, assuming insts/insiders don't sell with good news/good future.
  • C
    Captainkgood
    Just trying to connect some dots with potential acquisition angles. Astrazenaca just made a purchase, from today’s news:

    AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses.

    The offer values Alexion at $175 a share, a 45% premium to the closing price on Friday. It would be the largest deal for AstraZeneca since it was founded in a 1999 combination of British and Swedish companies, entrenching its position among the world’s 10 biggest drugmakers.”

    Did you read the part about rare diseases?

    And this snippet from the news release last week about their new board members. See who Ms Tetrault worked for?

    “Ms. Tetrault spent more than 20 years at AstraZeneca, including seven years as EVP for Human Resources and Corporate Affairs and a member of the company’s senior executive team. She is currently Lead Independent Director of Neo Genomics Clinical Laboratories, a cancer diagnostics company. On joining the Rhythm Board, she said, “Rhythm is forging new ground in rare genetic diseases of obesity with a commitment to organizational excellence and a true partnership with the community of patients, caregivers, advocacy groups and health care providers. I look forward to joining Camille on the Board and supporting Rhythm as it transforms into a global, commercial-stage company.”

    I would not be surprised if Astrazeneca has Rhythm on their radar. Or is it just a coincidence? Nice up day today!
  • C
    Captainkgood
    I’m new here. Do I understand correctly that approval could come in Oct or November?
  • J
    John
    I don't know but they are not creating an advisory
    committee and there not opening a plant.
    A delay into a market decline because of possible
    state shutdowns are the risks that I'm yielding too.
  • T
    Truthseeking
    "Patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency in the U.S. in the first quarter of 2021"
    I reckon this drug is targeting only a percentage of obese people due to the above paragraph.
    Anyone here can give an estimate how many people are affected with this disease?
  • J
    John
    Well the director bought 37,000 shares after hours today. That is a good sign!
    We expect information on a basket of trials before January.
    I think if this information is positive, it will imply more possibilities for the use of
    imviree. That would be good catalyst for the strike price.
Advertisement
Advertisement